[Prevalence of psychosis/substance abuse comorbidity. Clinical-epidemiological findings from different treatment settings in a large German city]
- PMID: 20232511
- DOI: 10.1007/s00115-009-2862-6
[Prevalence of psychosis/substance abuse comorbidity. Clinical-epidemiological findings from different treatment settings in a large German city]
Abstract
Comorbid substance use disorders in schizophrenia are of high clinical relevance, because they are common and they are mostly associated with an unfavourable long-term prognosis. Whereas the clinical impression suggests a continuous increase of substance use disorders in patients with schizophrenia over the last 10-20 years, results from epidemiological studies have been inconsistent. The aim of the present investigation was to study the prevalence of substance use disorders within a large sample of patients with schizophrenia in a large German city (Cologne). The prevalence data were examined in different treatment settings (outpatient vs inpatient, university hospital vs mental health hospital). Risk factors for substance use disorders and preferences for specific substances were analysed. The lifetime prevalence of comorbid substance use disorders in the entire sample of 2,337 patients with schizophrenia was 29.4%. However, the data varied substantially depending on the setting of treatment, with the highest comorbidity rates being prevalent in the inpatient sample. Alcohol and cannabis were the most commonly used substances. Commonly recognized risk factors for substance use disorders, such as being male and unmarried and having a low education level, were replicated.
Similar articles
-
[Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders].Encephale. 1996 Mar-Apr;22(2):95-101. Encephale. 1996. PMID: 8706627 French.
-
[Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].Encephale. 2002 Mar-Apr;28(2):160-8. Encephale. 2002. PMID: 11972143 French.
-
Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study.BMC Psychiatry. 2017 Dec 29;17(1):416. doi: 10.1186/s12888-017-1582-x. BMC Psychiatry. 2017. PMID: 29284436 Free PMC article.
-
[Epidemiology, etiology and treatment of patients with psychosis and co-morbid substance use disorder].Ther Umsch. 2018 Jun;75(1):37-43. doi: 10.1024/0040-5930/a000964. Ther Umsch. 2018. PMID: 29909760 Review. German.
-
[Dual diagnosis psychosis and substance use disorders: theoretical foundations and treatment].Z Kinder Jugendpsychiatr Psychother. 2008 Jul;36(4):245-53. doi: 10.1024/1422-4917.36.4.245. Z Kinder Jugendpsychiatr Psychother. 2008. PMID: 18654956 Review. German.
Cited by
-
[Substance use associated disorders: frequency in patients with schizophrenic and affective psychoses].Nervenarzt. 2013 Mar;84(3):315-25. doi: 10.1007/s00115-011-3459-4. Nervenarzt. 2013. PMID: 22476511 German.
-
Effect of criminal justice mandate on drug treatment completion in women.Am J Drug Alcohol Abuse. 2014 May;40(3):192-9. doi: 10.3109/00952990.2013.865033. Epub 2014 Feb 14. Am J Drug Alcohol Abuse. 2014. PMID: 24528184 Free PMC article.
-
Cannabis use and cognitive dysfunction.Indian J Psychiatry. 2011 Jul;53(3):187-91. doi: 10.4103/0019-5545.86796. Indian J Psychiatry. 2011. PMID: 22135433 Free PMC article. No abstract available.
-
An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.Eur Arch Psychiatry Clin Neurosci. 2011 Oct;261(7):489-508. doi: 10.1007/s00406-011-0196-4. Epub 2011 Feb 18. Eur Arch Psychiatry Clin Neurosci. 2011. PMID: 21331479
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical